Metformin in patients with ischemic heart disease and type 2 diabetes mellitus: mechanism of action and clinical efficiency

Metformin in patients with ischemic heart disease and type 2 diabetes mellitus: mechanism of action and clinical efficiency

Diabetes mellitus is one of the leading causes of death in modern society, primarily due to its cardiovascular complications. This factor drives search for novel pharmacologic agents to affect not only glycemic levels, but also the cardiovascular prognosis in diabetic patients with ischemic heart di...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ekaterina Nikodimovna Kravchuk, M M Galagudza
Format:	Article
Language:	English
Published:	Endocrinology Research Centre 2013-03-01
Series:	Сахарный диабет
Subjects:	diabetes mellitus type 2 metformin amp-activated protein kinase ischemic heart disease
Online Access:	https://www.dia-endojournals.ru/jour/article/view/3590
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Metformin as an activator of AMP-activated protein kinase. Known and new mechanisms of action
by: A. M. Mkrtumyan, et al.
Published: (2023-12-01)

Gestational Diabetes Management and Outcomes in South Jordan: Metformin Alone vs. Metformin-Insulin Therapy, A Retrospective Cohort Study
by: Ahlam M. Al-Kharabsheh, et al.
Published: (2024-11-01)

Rationale and Design of a Phase 2, Double-blind, Placebo-Controlled, Randomized Trial Evaluating AMP Kinase-Activation by Metformin in Focal Segmental Glomerulosclerosis
by: Gabriel C. Barsotti, et al.
Published: (2024-05-01)

Efficacy and safety of metformin-sitagliptin combination for the treatment of patients with diabetes mellitus and obesity
by: Alexander Sergeevich Ametov, et al.
Published: (2010-09-01)

Metformin inhibits melanin synthesis and melanosome transfer through the cAMP pathway
by: Xing Liu, et al.
Published: (2025-04-01)

DIABETES MELLITUS TYPE 2 TREATMENT IN CHILDREN AND ADOLESCENTS: METFORMIN AS A FIRST AGENT OF CHOICE
by: T. L. Kuraeva
Published: (2012-01-01)

Comparative assessment of treatment outcomes of empagliflozin add-on metformin and sitagliptin add-on metformin therapies in uncontrolled type 2 diabetes mellitus: findings from an observational study in Pakistan
by: Arif Ullah Khan, et al.
Published: (2025-08-01)

Side Effects Evaluation of the Use of Metformin and Glimepiride Combination In Type 2 Diabetes Mellitus Outpatients
by: Ni Nyoman Wahyu Udayani, et al.
Published: (2022-09-01)

Effects of metformin on body weight in patients with type 2 diabetes mellitus,receiving insulin analogue treatment
by: Tatiana Ivanovna Romantsova, et al.
Published: (2013-03-01)

Vitamin B12 Deficiency in Relation to Metformin Use in Adults with Type-2 Diabetes Mellitus
by: Anum Gul, et al.
Published: (2023-04-01)

The role of metformin in the modern strategy of treatment and prevention of type 2 diabetes mellitus
by: Olga Mikhailovna Smirnova
Published: (2010-09-01)

Phenotypic and genetic characteristics of patients with type 2 diabetes with different responses to metformin therapy in Novosibirsk region
by: Irina A. Bondar, et al.
Published: (2016-05-01)

Efficacy and Safety of Pioglitazone Add‐On in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials
by: Ubaid Khan, et al.
Published: (2025-05-01)

Metformin and cancer mortality
by: Lev Mikhaylovich Bershteyn
Published: (2010-09-01)

Taurine as a supplement for treating type II diabetes mellitus with metformin and DPP4 inhibitor
by: Tianyichen Xiao, et al.
Published: (2025-05-01)

An Updated Systematic Review and Meta‐Analysis on the Efficacy and Safety of Metformin as Add‐on Therapy to Insulin in Patients With Type 1 Diabetes
by: Mohammad Mahdi Masouri, et al.
Published: (2025-07-01)

Hormonal, metabolic and genetic predictors of metformin efficacy in patients with diabetes mellitus and cancer
by: Lev Mikhaylovich Bershteyn, et al.
Published: (2014-03-01)

Enhancing Diabetes Treatment: Comparing Pioglitazone/Metformin with Dapagliflozin Versus Basal Insulin/Metformin in Type 2 Diabetes
by: Lin Y, et al.
Published: (2025-03-01)

Metformin alleviates inflammatory response and severity rate of COVID-19 infection in elderly individuals
by: Xuguang Chen, et al.
Published: (2025-04-01)

INFLUENCE OF ROSUVASTATIN ON VASCULAR ENDOTHELIUM FUNCTIONAL STATE AND SYSTEMIC INFLAMMATION IN PATIENTS WITH ISCHEMIC HEART DISEASE AND DIABETES MELLITUS
by: I. M. Fushtey, et al.
Published: (2022-12-01)

A Study on Drug Utilization Pattern of Metformin and its Different Formulations Used in Patients with Type-2 Diabetes Mellitus in Tertiary Care Teaching Hospital
by: Dhaval B. Joshi, et al.
Published: (2018-01-01)

Metformin Affects Plasma Levels of Soluble Leptin Receptors in Type 2 Diabetes Mellitus and Metabolic Syndrome Patients
by: Najwa Ali, et al.
Published: (2023-06-01)

The influence of metformin and empagliflozin administration on gut microbiota in individuals with type 2 diabetes mellitus and hypothyroidism
by: K.A. Moskva, et al.
Published: (2024-06-01)

Prevalence of B12 deficiency among patients with type 2 diabetes mellitus using Metformin in Sulaimani governorate /Kurdistan region of Iraq
by: Govar Othman Abubakr, et al.
Published: (2023-06-01)

Multidimensional effects of metformin in patients with type 2 diabetes
by: Lyudmila A. Ruyatkina, et al.
Published: (2017-08-01)

Role of Metformin in Reducing the Incidence of Gestational Diabetes Mellitus in Obese Women
by: Shazia Rasul, et al.
Published: (2024-12-01)

Efficacy and safety of metformin for the treatment of gestational diabetes: a new approach to the problem
by: Anna I. Sazonova, et al.
Published: (2016-05-01)

Vitamin B12 Deficiency Among a Sample of Type 2 Diabetic Patients on Metformin in Erbil-City
by: Twana Mahmood Hamzah, et al.
Published: (2023-05-01)

Apoptotic and proliferative processes in the small intestine of rats with type 2 diabetes mellitus after metformin and propionic acid treatment
by: Larysa Natrus, et al.
Published: (2024-10-01)

Psychosocial factors in assessment of prognosis and prevention of ischemic heart disease associated with arterial hypertension and diabetes mellitus of type 2
by: N. P. Garganeeva
Published: (2013-12-01)

bFGF and TGFbeta1 growth factors, inflammatory markers (IL-6, TNF-alpha, CRP) and advanced glycation end-products (AGE, RAGE) in patients with ischemic heart disease and type 2 diabetes mellitus
by: Ekaterina Vladimirovna Ivannikova, et al.
Published: (2013-09-01)

Gallic acid improves the metformin effects on diabetic kidney disease in mice
by: Yan Hong, et al.
Published: (2023-12-01)

Downregulation of the Unfolded Protein Response Links Metformin Treatment to Good Clinical Outcomes in Colorectal Cancer Patients
by: Mary L. Fay, et al.
Published: (2025-02-01)

Metformin-mediated intestinal AMPK activation ameliorates PCOS through gut microbiota modulation and metabolic pathways
by: Yating Xu, et al.
Published: (2025-02-01)

ACUTE KIDNEY INJURY DUE TO METFORMIN-ASSOCIATED LACTIC ACIDOSIS
by: Svilena Aleksandrova, et al.
Published: (2025-08-01)

The Genetic Polymorphisms of rs161620 and rs2229611 in G6PC 3′UTR Are Associated With Metformin Efficacy in Chinese Type 2 Diabetes Mellitus
by: Cuilin Li, et al.
Published: (2025-04-01)

Gut microbiota’s role in the enhancement of type 2 diabetes treatment by a traditional Chinese herbal formula compared to metformin
by: Chengdong Xia, et al.
Published: (2025-05-01)

The influence of metformin treatment on the circulating proteomeResearch in context
by: Ben Connolly, et al.
Published: (2025-08-01)

Metabolic effects of nettle extract in diabetes mellitus
by: T. V. Yakimova, et al.
Published: (2011-10-01)

Association of metformin administration after septic shock with short-term and long-term survival in septic shock patients with diabetes
by: Bo-Yeong Jin, et al.
Published: (2025-05-01)